Berberine vs Retatrutide
A side-by-side research comparison of Berberine and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Berberine | Retatrutide |
|---|---|---|
| Full name | Berberine HCl | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | OTC supplement | Phase 3 Clinical Trial |
| Mechanism | Activates AMP-activated protein kinase (AMPK), the cellular energy sensor, improving insulin sensitivity, reducing hepatic glucose production, lowering LDL cholesterol, and favorably shifting the gut microbiome. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 371.81 Da | 5,200 Da (approximate) |
| Half-life | ~2.5 hours (poor systemic bioavailability) | 6 days |
| Bioavailability | Low (~5%); improved by dihydroberberine or piperine | High (SubQ) |
| Typical dose | 500 mg, 2-3x per day | 1-2 mg → titrate up to 12 mg |
| Frequency | 2-3x daily with meals | Once weekly |
| Route | Oral capsule | Subcutaneous injection |
Berberine reported benefits
- Improved insulin sensitivity
- Lower fasting blood glucose
- Reduced LDL and triglycerides
- AMPK activation (exercise-mimetic)
- Gut microbiome support
- Modest weight/waist reduction
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.